Combination of aminophylline (Phyllocontin Continus tablets) and salbutamol in the management of chronic obstructive airways disease.
1 The effect of a controlled release theophylline derivative (Phyllocontin Continus tablets) and an adrenoceptor agonist (salbutamol) was compared when taken singly and concomitantly in twenty patients with chronic bronchitis and additional reversible airways obstruction using a double-blind crossover technique. 2 The pulmonary function data showed a significant improvement in airways obstruction with an associated reduction in hyperinflation on combination therapy, as compared with either drug taken alone. 3 No significant improvement in patient symptoms occurred on combination therapy as compared with either drug taken alone. 4 A high incidence of side-effects was noted with both Phyllocontin Continus and salbutamol. Combination therapy, however, did not increase the frequency or severity of side-effects seen on either drug alone. 5 Although a proportion of patients showed evidence of intercurrent infection during the nine-week trial period, this did not appear to influence the results for the group as a whole.
D000328:Adult; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000628:Aminophylline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012129:Respiratory Function Tests
D003692:Delayed-Action Preparations; D000628:Aminophylline; D000420:Albuterol